IRF1 and neoplasm: In hepatocellular carcinoma and colon cancer, IRF1 has been shown to suppress the T-cell immune response and facilitate tumor immune escape by directly binding to the promoter of the programmed death ligand 1 (PD-L1) gene, thereby enhancing its transcription [15, 16].